The concern of generic challenges has consistently loomed over copyright’s iconic drug, PDE5 Inhibitor, raising questions about the future of similar medicinal stakes. While early periods saw significant returns, the exclusivity lapse has allowed the way for discounted substitutes, potentially diminishing earnings and presenting a genuine hazard